**Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus related Hepatocellular Carcinoma after Partial Hepatectomy**

Wei Dong1,2†, Kai Yan3†, Hua Yu1,2†, Lei Huo4, Zhihong Xian1,2, Yanqing Zhao1,2, Jutang Li5, Yuchan Zhang1,2, Zhenying Cao1,2, Yong Fu3\*, Wenming Cong1,2\*, Hui Dong1,2\*

1Department of Pathology, Eastern Hepatobiliary Surgery Hospital, the Second

Military Medical University, 225# Changhai Road, Shanghai, China.

2Key Laboratory of Signaling Regulation and Targeting Therapy of Liver Cancer, the Second Military Medical University, 225# Changhai Road, Shanghai, China.

3The Fifth Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital,

the Second Military Medical University, 225# Changhai Road, Shanghai, China.

4 Department of Radiology, Eastern Hepatobiliary Surgery Hospital, the Second

Military Medical University, 225# Changhai Road, Shanghai, China.

5Department of gynaecology and obstetrics, Tong Ren Hospital, Shanghai Jiao Tong University of Medicine, 1111# Xianxia Road,Shanghai, China.

†These authors contributed equally to this work

\* Correspondence:

Yong Fu

The Fifth Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital,

the Second Military Medical University, 225# Changhai Road, Shanghai, China.

Email:fuyg1982@163.com;

Wen-Ming Cong

Department of Pathology, Eastern Hepatobiliary Surgery Hospital, 225# Changhai Road, Shanghai, 200438, China.

Email wmcong@smmu.edu.cn ;

Hui Dong, Department of Pathology, Eastern

Hepatobiliary Surgery Hospital, 225# Changhai Road, Shanghai, 200438, China.

Email huidongwh@126.com

**Supplementary Figure Legends**

**Fig. S1** The diagrams with the flow of HCC patients.

**Fig. S2 The indexes in predicting sorafenib benefit in patients stratified by prognostic factors.**

The OS of patients in overall cohort stratified by levels of GPC3(**a**), pERK(**b**), pAKT(**c**), Gender(**d**), Age(**e**), Serum AFP(**f**), MVI(**g**), BCLC stage(**h**), TNM stage(**i**), Child-pugh stage(**j**), Serum ALT(**k**), Serum AST(**l**), Serum ALP(**m**), Serum Cre(**n**) were compared between the sorafenib and control cohorts.

**Fig. S3** **Kaplan-Meier survival curves of TTR in the sorafenib cohort.** GPC3(**a**), pERK(**b**), pAKT(**c**), BCLC staging system(**d**), serum AST(**e**) and nomogram stage(**f**) of sorfenib cohort.

**Fig. S4 Kaplan-Meier survival curves of OS in the control cohort.** GPC3(**a**), pERK(**b)**, pAKT(**c**), BCLC staging system(**d**), serum AST(**e**) and nomogram stage(**f**) of control cohort.

**Fig. S5 The nomogram stage in predicting sorafenib benefit in overall cohort.** The OS were compared between the sorafenib and control cohorts of nomogram stageⅠ(**a**), stageⅡ(**b**) and stage Ⅲ(**c**).